Stamford-based Cara Therapeutics, which recently gained federal approval for its first drug, ranks No. 14 in professional-services firm Deloitte’s latest standings of the fastest-growing technology firms in North America.
“We’re thrilled to be recognized by Deloitte as one of the fastest-growing companies in North America. We’re especially pleased to be ranked No. 2 among companies in the tri-state area,” said Cara CEO and President Christopher Posner.